Henry Pelish, PhD
Henry is a multidisciplinary scientist skilled in cancer biology, chemical biology and organic synthesis. He contributed to the creation of Nuvalent and joined full-time in 2018.
Henry’s career has spanned multiple industry and academic appointments. Prior to joining Nuvalent, Henry was a group leader in the laboratory of Professor Matthew Shair at Harvard University. In that role, he built and led a team that discovered a new target, mechanism of action and therapeutic opportunity for treatment of acute myeloid leukemia. In parallel, he spearheaded a drug discovery program that culminated in a licensing deal and research agreement between Harvard and Merck in 2016, and subsequently served as a member of the Harvard-Merck Joint Research Committee.
Henry earned a PhD in Chemistry from Harvard University and is an avid runner and swimmer.